MEASLES VACCINATION USING MVVAC2

使用 MVVAC2 进行麻疹疫苗接种

• 批准号: 8357357
• 负责人: Michael B. McChesney
• 金额: $ 5.04万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357357
• 关键词: Aliquot; Asians; Attenuated; California; Canine Distemper; Disease; Dose; Funding; Grant; Human; Macaca; Macaca mulatta; Marketing; Measles; Measles Vaccine; Measles virus; Modeling; Monkeys; National Center for Research Resources; Pathogenesis; Policies; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Source; Testing; United States National Institutes of Health; Vaccination; Vaccines; Vero Cells; Vial device; Virus; Virus Diseases; cost; mortality; nonhuman primate; pathogen; tissue culture

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Measles virus (MV) is a natural human pathogen, but several species of Asian macaque and some other nonhuman primates are susceptible. The pathogenesis of measles is modeled very closely in rhesus and cynomolgus macaques. MV infection and disease, with significant mortality, can be widespread in primate colonies. Several primate centers, including the CNPRC, have used regular, annual measles vaccination to protect susceptible species from measles introduced by humans. This policy has been effective for many years; but currently, the measles or canine distemper vaccines that have been used successfully have been taken off the market. There has been no measles vaccination of primates at the CNPRC for the last 3 years. We have tested a molecularly cloned measles vaccine strain, derived from a vial of the Moraten strain measles vaccine, which we designate MVvac2. This virus infects rhesus monkeys with an attenuated pathogenesis, and the monkeys are protected from pathogenic MV challenge. This vaccine virus can be grown in Vero cells to titers of 105 - 106 tissue culture infectious doses per ml, thus it would be a practical vaccine for primate colony management. Vaccine stocks could be produced in large volume ( 100 doses) and cryopreserevd in aliquots that would be thawed immediately before use.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 麻疹病毒（MV）是一种天然的人类病原体，但是亚洲猕猴和其他一些非人类灵长类动物易感性。麻疹的发病机理在恒河猴和膀胱猕猴中非常紧密地建模。 MV感染和疾病具有显着的死亡率，在灵长类动物的殖民地中可能会广泛。包括CNPRC在内的几个灵长类动物中心已经使用了常规的每年麻疹疫苗接种，以保护易感物种免受人类引入的麻疹。该政策已经有效了很多年。但是目前，已成功使用的麻疹或犬科脱水疫苗已被从市场上取出。在过去的三年中，CNPRC的灵长类动物的麻疹接种疫苗没有疫苗接种。我们已经测试了一种分子克隆的麻疹疫苗菌株，该疫苗菌株源自莫拉特菌菌株的小瓶疫苗，我们将其指定为MVVAC2。该病毒感染带有衰减发病机理的恒河猴，并保护猴子免受致病性MV挑战的保护。该疫苗病毒可以在Vero细胞中生长为105-106组织培养的滴度，每毫升，这将是灵长类动物菌落管理的实用疫苗。可以大量生产疫苗（100剂），在使用前将在使用前融化的等分试样中生产疫苗。